In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.
Gram-negative (n=2213) and Gram-positive (n=2424) pathogens isolated from patients in 13 Canadian hospitals in 2014 and 2015 were tested for in vitro susceptibility to eravacycline and comparators using the Clinical and Laboratory Standards Institute broth microdilution method. The concentration of eravacycline inhibiting 90% of isolates (MIC90) ranged from 0.5 to 2μg/mL for 9 species of Enterobacteriaceae tested (n=2067). Eravacycline activity was largely unaffected by extended-spectrum β-lactamase phenotypes in Escherichia coli (n=141) and Klebsiella pneumoniae (n=21). Eravacycline was active against Acinetobacter baumannii (n=28; MIC90, 0.5μg/mL) and Stenotrophomonas maltophilia (n=118; MIC90, 4μg/mL). Eravacycline MIC90 for staphylococci (n=1653), enterococci (n=289), and streptococci (n=482) ranged from 0.12 to 0.25, 0.06 to 0.12, and 0.015 to 0.06μg/mL, respectively. Eravacycline's potency was equivalent to or 2- to 4-fold greater than tigecycline against Enterobacteriaceae and Gram-positive cocci tested. Eravacycline demonstrates promising activity against recent clinical Gram-negative and Gram-positive bacteria, including multidrug-resistant pathogens.